E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Arginase 1 deficiency Hyperargininemia |
|
E.1.1.1 | Medical condition in easily understood language |
Arginase deficiency Hyperargininemia |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10062695 |
E.1.2 | Term | Arginase deficiency |
E.1.2 | System Organ Class | 10010331 - Congenital, familial and genetic disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the safety and tolerability of intravenous (IV) administration of AEB1102 in patients with Arginase I deficiency and hyperargininemia |
|
E.2.2 | Secondary objectives of the trial |
1) To determine the effects of AEB1102 administered IV on plasma arginine concentrations 2)To determine the effects of AEB1102 administered IV on plasma guanidino compounds 3) To characterize the pharmacokinetic (PK) profile of AEB1102 administered IV |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
A patient must meet all of the following criteria to be enrolled in this study: PART 1 1. Is male or female: pediatric patients ≥ 2 to < 18 years of age and adult patients ≥ 18 years of age 2. Has documented diagnosis of Arginase 1 deficiency, with: • Hyperargininemia: plasma arginine levels from one or more of 3 baseline samples > 250 μM or 2 of 3 baseline samples > 200 μM (note: 2 of the 3 samples can be collected by home health care personnel) AND EITHER • Mutation in the arginase I gene OR • Deficiency in red blood cell (RBC) arginase activity 3. Has adequate organ function defined as follows: • Bone marrow: Hemoglobin ≥10 g/dL; WBC >3.0 × 10^9/L; platelet count ≥ 100,000/μL • Hepatic (bilirubin): Total bilirubin ≤ 2.0 × upper limit of normal (ULN) • Hepatic (transaminases): EITHER • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 × ULN OR • AST and/or ALT > 3.0 × ULN but both ≤ 5.0 × ULN, and in the opinion of the Investigator, related to Arginase 1 deficiency • Renal: serum creatinine < 1.5 × ULN 4. If female and of child-bearing potential, has a negative serum pregnancy test within 7 days before enrollment 5. If the patient (male or female) is engaging in sexual activity that could lead to pregnancy, must be surgically sterile, post-menopausal (female), or must agree to use a highly effective method of birth control during the study and for a minimum of 30 days after the last study drug administration. Highly effective methods of contraception include: combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation; progesterone-only hormonal contraception associated with inhibition of ovulation; intrauterine device (IUD); or intrauterine hormone-releasing system (IUS). 6. Patient or legal guardian is able and willing to provide written informed consent and, where required, assent, and to comply with all requirements of study participation (including all study procedures and continuation of prescribed diet modification) prior to any screening procedures.
PART 2 INCLUSION CRITERION: 1. Did not experience any adverse event in Part 1 that, in the opinion of the Investigator in consultation with the Sponsor, would preclude continued study participation and dosing of AEB1102 |
|
E.4 | Principal exclusion criteria |
A patient is excluded from this study if he/she meets any of the following criteria 1 Had transfusion of ≥ 2 units of RBCs within the 60 days before enrollment 2. Currently has an active infection requiring systemic treatment 3. Known infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C 4. Had unstable hyperammonemia requiring hospitalization within the 14 days before enrollment 5. Currently has any comorbid condition or laboratory abnormality that in the opinion of the Investigator might compromise the patient's safety, might interfere with participation in the trial, or might interfere with the interpretation of trial results 6. Is currently participating in another therapeutic clinical trial 7. Has received any investigational agent within 30 days of enrollment 8. Has a history of hypersensitivity to PEG or any other component of the AEB1102 (Co-ArgI-PEG) formulation 9. If female, is lactating or breastfeeding |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Safety and tolerability will be assessed by: • Adverse events/serious adverse events • Physical examinations • Vital signs • ECGs • Clinical laboratory studies (serum chemistries, hematology, coagulation, urinalysis) • Low plasma arginine levels associated with clinically significant symptoms • Clinically significant hyperammonemia • Immunogenicity assessments (levels of anti-AEB1102 and anti-PEG antibodies) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Part 1 At screening: PE, Vital signs, Clinical lab studies, ECG, AEs, Arginine, ornithine, Ammonia, ALT & AST At Baseline: Tryptase & complement C3, AEs, Arginine, ornithine, Ammonia, ALT & AST Wk 1 (Dose 1), 3 (Dose 2*), 5 (Dose 3*), 7 (Dose 4*), 9 (Dose 5-7*) & Follow up (2 wks after last dose) : All parameters Wk 2, 4, 6, 8 & 10: Vital signs, AEs, Arginine, ornithine, Ammonia, ALT & AST *Doses 2 to 7 only needed if arginine suppression or stopping criteria not met. Procedures would continue on an every 2 week interval. Please refer the protocol for more details.
Part 2 Each patient will receive up to 7 weeks (8 doses) of repeat dose therapy, primary end point measures for part 2 are detailed in the protocol CAEB1102-101A (Amend 3.0, May 17, 2018) Page 18, Table 2. |
|
E.5.2 | Secondary end point(s) |
Pharmacokinetic analyses • T1/2, Tmax, Cmax, AUC0-t, AUC0-∞, CL, and Vss
Plasma arginine levels • Magnitude, onset, and duration of changes to arginine levels after AEB1102 administration
Plasma guanidino compounds levels • Magnitude, onset, and duration of changes to guanidino compounds levels after AEB1102 administration |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Part 1
AEB1102 PK sampling: Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 and Follow up (2 weeks after last dose)
Plasma arginine levels and Plasma guanidino compounds levels: Plasma Arginine and guanidino compounds samples will be collected at the same time points as AEB1102 PK Samples and in addition, will also be collected at the screening visit, at the baseline visit and one additional point between screening and Visit 1
Part 2 AEB1102 PK sampling, Plasma arginine levels and Plasma guanidino compounds levels: At Baseline, Week 1, 2, 3, 4, 5, 6, 7, 8/EOT and Follow up (2 weeks after final dose) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Yes |
E.7.1.3.1 | Other trial type description |
Safety and tolerability study |
|
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 2 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Canada |
Portugal |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS (last visit of the last subject) |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 8 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 2 |
E.8.9.2 | In all countries concerned by the trial days | 0 |